APRIL 17, 2020 7:30AM EDT
Todos Medical also announces it has received the independent third-party valuation report required to complete the full acquisition of its joint venture Breakthrough Diagnostics, Inc.
Through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. (OTC: AMBS), Todos is also actively involved with the development of blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. Todos expected to complete the remaining unowned interest in Breakthrough in the second quarter of 2020
https://investor.todosmedical.com/news-events...s-board-of
APRIL 09, 2020 9:03AM EDT
Acquisition of Breakthrough Diagnostics, Inc. for Alzheimer’s blood diagnostic LymPro Test™
The Company has been seeking to complete the acquisition of Breakthrough Diagnostics due to the tremendous potential of the LymPro Test™ as a diagnostic blood test for Alzheimer’s disease. We have commissioned an independent third-party valuation of LymPro in order to fulfill the necessary requirements to complete the acquisition later this quarter.
https://investor.todosmedical.com/news-events...ate-update
FEBRUARY 06, 2020
Diagnostics
The Company‘s 80.01%-owned subsidiary Breakthrough Diagnostics, Inc., currently a joint venture with Todos Medical, Ltd...
Todos has exercised its exclusive option to acquire Amarantus’ remaining ownership in Breakthrough in exchange for approximately 49% ownership of Todos. The transaction is expected to close in the first half of 2020
https://www.amarantus.com/news/press-releases...ics-enters
FEBRUARY 04, 2020
Diagnostics
The Company‘s 80.01%-owned subsidiary Breakthrough Diagnostics, Inc., currently a joint venture with Todos Medical...
Todos has exercised its exclusive option to acquire Amarantus’ remaining ownership in Breakthrough in exchange for approximately 49% ownership of Todos. The transaction is expected to close in the frist half of 2020.
https://www.amarantus.com/news/press-releases...areholders
FEBRUARY 28, 2019
Under the terms of the JV Agreement, Todos Medical, has an exclusive option to acquire the remaining 80.01% of Breakthrough Diagnostics in exchange for an additional 30.01% of Todos Medical’s shares
https://www.amarantus.com/news/press-releases...-finalizes
JANUARY 07, 2019
Breakthrough Diagnostics
In December 2018, Amarantus announced a Joint Venture agreement with Todos Medical (OTC:TOMDF) to develop the Alzheimer's blood diagnostic 'LymPro Test 2.0'. The Joint Venture is called Breakthrough Diagnostics, Inc. ("Breakthrough"
. Under the terms of the agreement, Amarantus will receive 19.99% of equity in Todos, and Todos will receive 19.99% of the equity in Breakthrough, with Todos also providing initially $500,000 to fund certain license and development costs, as well as the retention of key management to drive the program forward. Todos has an option to acquire the remaining 80.01% of Breakthrough upon the achievement of certain milestones, in exchange for a total of 50% of Todos shares (inclusive of shares issued to Amarantus via the Joint Venture). Todos owns rights to potentially revolutionary technology in the early detection of cancer based on proprietary blood immune markers, with tests for breast cancer and colorectal cancer having already received regulatory authorization in Europe. We expect the Joint Venture transaction to be completed in the first quarter of 2019.https://www.amarantus.com/news/press-releases/detail/2105/amarantus-provides-2019-roadmap
NOVEMBER 14, 2019 11:02AM EST
About Breakthrough Diagnostics, Inc.
Breakthrough Diagnostics, Inc. is a joint venture owned by Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) (80.01%) and Todos Medical Ltd. (19.99%). Breakthrough has been assigned the intellectual property and other rights to the LymPro Test®, a diagnostic blood test for Alzheimer’s disease, as well as rights to other neurological diagnostics testing intellectual property. Todos Medical has provided Amarantus with notice of Todos’ decision to exercise its exclusive option to acquire the 80.01% of Breakthrough Diagnostics that it currently does not own.
https://investor.todosmedical.com/news-events...enrollment
Aloha
Todos Medical also announces it has received the independent third-party valuation report required to complete the full acquisition of its joint venture Breakthrough Diagnostics, Inc.
Through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. (OTC: AMBS), Todos is also actively involved with the development of blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. Todos expected to complete the remaining unowned interest in Breakthrough in the second quarter of 2020
https://investor.todosmedical.com/news-events...s-board-of
APRIL 09, 2020 9:03AM EDT
Acquisition of Breakthrough Diagnostics, Inc. for Alzheimer’s blood diagnostic LymPro Test™
The Company has been seeking to complete the acquisition of Breakthrough Diagnostics due to the tremendous potential of the LymPro Test™ as a diagnostic blood test for Alzheimer’s disease. We have commissioned an independent third-party valuation of LymPro in order to fulfill the necessary requirements to complete the acquisition later this quarter.
https://investor.todosmedical.com/news-events...ate-update
FEBRUARY 06, 2020
Diagnostics
The Company‘s 80.01%-owned subsidiary Breakthrough Diagnostics, Inc., currently a joint venture with Todos Medical, Ltd...
Todos has exercised its exclusive option to acquire Amarantus’ remaining ownership in Breakthrough in exchange for approximately 49% ownership of Todos. The transaction is expected to close in the first half of 2020
https://www.amarantus.com/news/press-releases...ics-enters
FEBRUARY 04, 2020
Diagnostics
The Company‘s 80.01%-owned subsidiary Breakthrough Diagnostics, Inc., currently a joint venture with Todos Medical...
Todos has exercised its exclusive option to acquire Amarantus’ remaining ownership in Breakthrough in exchange for approximately 49% ownership of Todos. The transaction is expected to close in the frist half of 2020.
https://www.amarantus.com/news/press-releases...areholders
FEBRUARY 28, 2019
Under the terms of the JV Agreement, Todos Medical, has an exclusive option to acquire the remaining 80.01% of Breakthrough Diagnostics in exchange for an additional 30.01% of Todos Medical’s shares
https://www.amarantus.com/news/press-releases...-finalizes
JANUARY 07, 2019
Breakthrough Diagnostics
In December 2018, Amarantus announced a Joint Venture agreement with Todos Medical (OTC:TOMDF) to develop the Alzheimer's blood diagnostic 'LymPro Test 2.0'. The Joint Venture is called Breakthrough Diagnostics, Inc. ("Breakthrough"
. Under the terms of the agreement, Amarantus will receive 19.99% of equity in Todos, and Todos will receive 19.99% of the equity in Breakthrough, with Todos also providing initially $500,000 to fund certain license and development costs, as well as the retention of key management to drive the program forward. Todos has an option to acquire the remaining 80.01% of Breakthrough upon the achievement of certain milestones, in exchange for a total of 50% of Todos shares (inclusive of shares issued to Amarantus via the Joint Venture). Todos owns rights to potentially revolutionary technology in the early detection of cancer based on proprietary blood immune markers, with tests for breast cancer and colorectal cancer having already received regulatory authorization in Europe. We expect the Joint Venture transaction to be completed in the first quarter of 2019.https://www.amarantus.com/news/press-releases/detail/2105/amarantus-provides-2019-roadmap NOVEMBER 14, 2019 11:02AM EST
About Breakthrough Diagnostics, Inc.
Breakthrough Diagnostics, Inc. is a joint venture owned by Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) (80.01%) and Todos Medical Ltd. (19.99%). Breakthrough has been assigned the intellectual property and other rights to the LymPro Test®, a diagnostic blood test for Alzheimer’s disease, as well as rights to other neurological diagnostics testing intellectual property. Todos Medical has provided Amarantus with notice of Todos’ decision to exercise its exclusive option to acquire the 80.01% of Breakthrough Diagnostics that it currently does not own.
https://investor.todosmedical.com/news-events...enrollment
Aloha
4
